Arena Pharmaceuticals (ARNA) 4.46 $ARNA
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
PR Newswire - Fri Aug 01, 3:30AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2014.
'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific
at The Street - Thu Jul 31, 5:00AM CDT
Cramer isn't crazy about Nimble Storage but thinks Pitney Bowes stock can go higher.
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
PR Newswire - Wed Jul 30, 7:00AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise as a Predictor of Week 52 Weight-Loss Outcomes," was recently published in the online issue of Obesity, the official peer reviewed journal of The Obesity Society. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin.
Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category
PR Newswire - Tue Jul 29, 7:00AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ® (lorcaserin HCl) has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013.
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
PR Newswire - Fri Jul 25, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, August 1, 2014. That same day, Arena will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel
PR Newswire - Mon Jul 21, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ® (lorcaserin HCl) with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limited. Under the agreement, Arena granted Abic the rights to market and distribute BELVIQ in Israel for weight loss or weight management in obese and overweight patients, subject to regulatory approval by the State of Israel Ministry of Health (MOH).
The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...
Anti-Obesity Drugs Market 2014-2020 - Global Strategic Business Report
M2 - Thu Jul 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n8gsfc/antiobesity) has announced the addition of the "Anti-Obesity Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as: - Arena Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Novo Nordisk - Orexigen Therapeutics, Inc. - Rhythm Pharmaceuticals Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Scenario 3. Market Trends, Drivers And Challenges 4. Select Pipeline Drug Candidates 5. Select Scientific Breakthroughs 6. Obesity An Introduction 7. Obesity Treatment 8. Anti-Obesity Drugs An Insight 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 33 (including Divisions/Subsidiaries 34) - The United States (14) - Japan (4) - Europe (
- The United Kingdom (3) - Rest of Europe (5) - Asia-Pacific (Excluding Japan) ( For more information visit http://www.researchandmarkets.com/research/n8...ntiobesity
Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 3:30PM CDT
The U.S. Patent and Trademark Office issued a new patent to Arena Pharmaceuticals, Inc. (ARNA) for its pain candidate APD371.
Cannabis Based Healing Products Lead Commercialization For Medical Marijuana Patients - Company Introduces New Edible CBD-Rich Product Line
PR Newswire - Wed Jul 16, 7:30AM CDT
Cannabis & Pharmaceutical companies announce progress on product development and display a promise for growth as industry matures: Novagant Corp. (OTC: NVGT), GreenGro Technologies, Inc. (OTC: GRNH), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), American Green, Inc. (OTC: ERBB) and Creative Edge Nutrition, Inc. (OTC: FITX)
Arena Pharmaceuticals receives patent for APD371 covering composition of matter and related compounds
M2 - Wed Jul 16, 6:51AM CDT
Medicine company Arena Pharmaceuticals (NasdaqGS:ARNA) reported on Tuesday the receipt of the US Patent Number 8,778,950 entitled "Cannabinoid Receptor Modulators" for APD371.
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks." -- Arena Pharmaceuticals CEO Jack...
Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office
PR Newswire - Tue Jul 15, 3:31PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2). Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.
Fed Chair Yellen Says Small Biotech Stocks Over-Valued
at The Street - Tue Jul 15, 12:10PM CDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Downtrend Call Working As Arena Pharmaceuticals Stock Falls 16.3% (ARNA)
Comtex SmarTrend(R) - Thu Jul 10, 4:48PM CDT
SmarTrend identified a Downtrend for Arena Pharmaceuticals (NASDAQ:ARNA) on June 2nd, 2014 at $6.05. In approximately 1 month, Arena Pharmaceuticals has returned 16.29% as of today's recent price of $5.06.
Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb
George Budwell, The Motley Fool - Motley Fool - Thu Jul 10, 7:54AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Allergan , Arena Pharmaceuticals , and Bristol-Myers Squibb . Allergan looking to "upsize" to fight takeover bid It's no secret that Allergan has been...
Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV
PR Newswire - Thu Jul 10, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in the United States.
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
PR Newswire - Fri Aug 01, 3:30AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2014.
'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific
at The Street - Thu Jul 31, 5:00AM CDT
Cramer isn't crazy about Nimble Storage but thinks Pitney Bowes stock can go higher.
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
PR Newswire - Wed Jul 30, 7:00AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise as a Predictor of Week 52 Weight-Loss Outcomes," was recently published in the online issue of Obesity, the official peer reviewed journal of The Obesity Society. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin.
Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category
PR Newswire - Tue Jul 29, 7:00AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ® (lorcaserin HCl) has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013.
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
PR Newswire - Fri Jul 25, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, August 1, 2014. That same day, Arena will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel
PR Newswire - Mon Jul 21, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ® (lorcaserin HCl) with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limited. Under the agreement, Arena granted Abic the rights to market and distribute BELVIQ in Israel for weight loss or weight management in obese and overweight patients, subject to regulatory approval by the State of Israel Ministry of Health (MOH).
The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...
Anti-Obesity Drugs Market 2014-2020 - Global Strategic Business Report
M2 - Thu Jul 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n8gsfc/antiobesity) has announced the addition of the "Anti-Obesity Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as: - Arena Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Novo Nordisk - Orexigen Therapeutics, Inc. - Rhythm Pharmaceuticals Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Scenario 3. Market Trends, Drivers And Challenges 4. Select Pipeline Drug Candidates 5. Select Scientific Breakthroughs 6. Obesity An Introduction 7. Obesity Treatment 8. Anti-Obesity Drugs An Insight 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 33 (including Divisions/Subsidiaries 34) - The United States (14) - Japan (4) - Europe (
- The United Kingdom (3) - Rest of Europe (5) - Asia-Pacific (Excluding Japan) ( For more information visit http://www.researchandmarkets.com/research/n8...ntiobesity Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 3:30PM CDT
The U.S. Patent and Trademark Office issued a new patent to Arena Pharmaceuticals, Inc. (ARNA) for its pain candidate APD371.
Cannabis Based Healing Products Lead Commercialization For Medical Marijuana Patients - Company Introduces New Edible CBD-Rich Product Line
PR Newswire - Wed Jul 16, 7:30AM CDT
Cannabis & Pharmaceutical companies announce progress on product development and display a promise for growth as industry matures: Novagant Corp. (OTC: NVGT), GreenGro Technologies, Inc. (OTC: GRNH), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), American Green, Inc. (OTC: ERBB) and Creative Edge Nutrition, Inc. (OTC: FITX)
Arena Pharmaceuticals receives patent for APD371 covering composition of matter and related compounds
M2 - Wed Jul 16, 6:51AM CDT
Medicine company Arena Pharmaceuticals (NasdaqGS:ARNA) reported on Tuesday the receipt of the US Patent Number 8,778,950 entitled "Cannabinoid Receptor Modulators" for APD371.
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks." -- Arena Pharmaceuticals CEO Jack...
Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office
PR Newswire - Tue Jul 15, 3:31PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2). Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.
Fed Chair Yellen Says Small Biotech Stocks Over-Valued
at The Street - Tue Jul 15, 12:10PM CDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Downtrend Call Working As Arena Pharmaceuticals Stock Falls 16.3% (ARNA)
Comtex SmarTrend(R) - Thu Jul 10, 4:48PM CDT
SmarTrend identified a Downtrend for Arena Pharmaceuticals (NASDAQ:ARNA) on June 2nd, 2014 at $6.05. In approximately 1 month, Arena Pharmaceuticals has returned 16.29% as of today's recent price of $5.06.
Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb
George Budwell, The Motley Fool - Motley Fool - Thu Jul 10, 7:54AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Allergan , Arena Pharmaceuticals , and Bristol-Myers Squibb . Allergan looking to "upsize" to fight takeover bid It's no secret that Allergan has been...
Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV
PR Newswire - Thu Jul 10, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in the United States.
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
